Systemic Inflammatory Response Syndrome Treatment Market is expected to reach US$ 5.54 Bn. at a CAGR of 8 % during the forecast period 2029. The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. The systemic inflammatory response syndrome (SIRS) describe the complex pathophysiologic response to an injury like acute inflammation, surgery, infection, trauma, burns, ischemia or reperfusion, pancreatitis, and others. SIRS is clinical response to a nonspecific onslaught of either infectious or noninfectious origin. Infection is an obtuse cause of systemic inflammatory response syndrome but, a number of additional indications including trauma, neoplasm, burn injury, ARDS, pancreatitis, and dysfunctional macrophage activation are also recognized causes.To know about the Research Methodology :- Request Free Sample Report
Systemic Inflammatory Response Syndrome Treatment Market Drivers and Restrains
The author Kaukonen et al. in their study of over 130000 septic patients recognized that one out of eight patients in their observational study come under SIRS criteria. Global Systemic Inflammatory Response Syndrome Treatment Market Drives, Because of increase in patient admissions in hospitals and ambulatory surgical centers. Thanks to the recognition that a diverse group of injuries created a common inflammatory response in the host and provided attractive targets for new anti-inflammatory molecules considered to provide specific treatment or to prevent further propagation. Current application of these new anti-inflammatory strategies demanded identification of early clinical markers that could be evaluated in real-time and was more likely to define a population of patients that would have a valuable response to the targeted involvement. Researchers in the field documented the importance of interrupting these inflammatory pathways as soon as possible in order to get success. If ability to recognize the septic patient at the initial phase, then this strategy was going to have a potential to produce the desired benefit. But, restricted availability of therapeutics for SIRS, lack of quality care for critically-ill patients are expected to hamper the growth of the global SIRS treatment market during the forecast period. Manufacturers in the Systemic Inflammatory Response Syndrome Treatment are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers. In terms of market segmentation, the others segment held a major share of the systemic inflammatory response syndrome treatment market in 2018. The segment is expected to dominate the market during the forecast period, because of increased penetration of treatment. On the basis of end user, the hospitals and ambulatory surgical centers segment is expected for a significant share of the global systemic inflammatory response syndrome treatment market. The hospitals and ambulatory surgical centers segment is dominate the global market during the forecast period, because of increase in inpatient admissions in hospitals and ambulatory surgical centers. However, limited availability of therapeutics for Systemic Inflammatory Response Syndrome Treatment and lack of good care for critically-ill patients are anticipated to hinder the growth of the global SIRS treatment market during the forecast period.Systemic Inflammatory Response Syndrome Treatment Market Regional Analysis
In the global market, North America is driven primarily by increase in the occurrence of SIRS and rise in knowledge about SIRS among healthcare professionals. Furthermore, surge in government initiatives to non-infectious and infectious diseases, increase in the geriatric population that is at high risk. Large number of key players in North America focusing on research and developments activities to introduce technologically-advanced systemic inflammatory response syndrome treatments with better designs drive the market in the region. Furthermore, Europe held the second-largest dominant market in 2018. Asia Pacific is a comparatively untapped market as compared to developed regions. The objective of the report is to present comprehensive analysis of Global Systemic Inflammatory Response Syndrome Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Systemic Inflammatory Response Syndrome Treatment Market dynamics, structure by analyzing the market segments, and project the Global Systemic Inflammatory Response Syndrome Treatment Market size. Clear representation of competitive analysis of key players by Systemic Inflammatory Response Syndrome Treatment Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Systemic Inflammatory Response Syndrome Treatment Market make the report investor’s guide.Systemic Inflammatory Response Syndrome Treatment Market Scope: Inquire before buying
Systemic Inflammatory Response Syndrome Treatment Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2017 to 2022 Market Size in 2022: US $ 3.23 Bn. Forecast Period 2023 to 2029 CAGR: 8 % Market Size in 2029: US $ 5.54 Bn. Segments Covered: by Therapy • Antimicrobial Therapy in SIRS • Steroid Therapy in SIRS by Organ System • Acute kidney injury • Multiple organ dysfunction syndrome Systemic Inflammatory Response Syndrome Treatment Market, by Region
• North America (United States, Canada and Mexico) • Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) • Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) • Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) • South America (Brazil, Argentina Rest of South America)Systemic Inflammatory Response Syndrome Treatment Market, Major Players
• UnitedHealth Group • CytoSorbents Corporation • RegeneRx Biopharmaceuticals, Inc. • Endacea Inc. • Adrenomed AG • GlaxoSmithKline plc • Asahi Kasei Corporation • Cardinal Health • Smith & • Nephew plc • ConvaTec, Inc. • AstraZeneca • Orion Corporation • CHIESI Farmaceutici S.p.A. • Mylan N.V Frequently Asked Questions: 1. Which region has the largest share in Global Systemic Inflammatory Response Syndrome Treatment Market? Ans: North America region held the highest share in 2022. 2. What is the growth rate of Global Systemic Inflammatory Response Syndrome Treatment Market? Ans: The Global Systemic Inflammatory Response Syndrome Treatment Market is growing at a CAGR of 8% during forecasting period 2023-2029. 3. What is scope of the Global Systemic Inflammatory Response Syndrome Treatment Market report? Ans: Global Systemic Inflammatory Response Syndrome Treatment Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Systemic Inflammatory Response Syndrome Treatment Market? Ans: The important key players in the Global Systemic Inflammatory Response Syndrome Treatment Market are – UnitedHealth Group, CytoSorbents Corporation, RegeneRx Biopharmaceuticals, Inc., Endacea Inc., Adrenomed AG, GlaxoSmithKline plc, Asahi Kasei Corporation, Cardinal Health, Smith &, Nephew plc, ConvaTec, Inc., AstraZeneca, Orion Corporation, CHIESI Farmaceutici S.p.A., and Mylan N.V 5. What is the study period of this Market? Ans: The Global Systemic Inflammatory Response Syndrome Treatment Market is studied from 2022 to 2029.
Global Systemic Inflammatory Response Syndrome Treatment Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Systemic Inflammatory Response Syndrome Treatment Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast 6.1. Global Systemic Inflammatory Response Syndrome Treatment Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast, by Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Type 7.4. Global Systemic Inflammatory Response Syndrome Treatment Market Size (US$ Bn) Forecast, by Type 7.5. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis, by Type 7.6. Global Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Type 8. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast, by Organ System 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Organ System 8.4. Global Systemic Inflammatory Response Syndrome Treatment Market Size (US$ Bn) Forecast, by Organ System 8.5. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis, by Organ System 8.6. Global Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Organ System 9. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast, by Indication 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Indication 9.4. Global Systemic Inflammatory Response Syndrome Treatment Market Size (US$ Bn) Forecast, by Indication 9.5. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis, by Indication 9.6. Global Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Indication 10. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast, by End Users 10.1. Introduction and Definition 10.2. Key Findings 10.3. Global Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by End Users 10.4. Global Systemic Inflammatory Response Syndrome Treatment Market Size (US$ Bn) Forecast, by End Users 10.5. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis, by End Users 10.6. Global Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by End Users 11. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis, by Region 11.1. Global Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Region 11.2. Global Systemic Inflammatory Response Syndrome Treatment Market Size (US$ Bn) Forecast, by Region 11.3. Global Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Region 12. North America Systemic Inflammatory Response Syndrome Treatment Market Analysis 12.1. Key Findings 12.2. North America Systemic Inflammatory Response Syndrome Treatment Market Overview 12.3. North America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Type 12.4. North America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 12.4.1. Antimicrobial Therapy in SIRS 12.4.2. Steroid Therapy in SIRS 12.5. North America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Organ System 12.6. North America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 12.6.1. Acute kidney injury 12.6.2. Multiple organ dysfunction syndrome 12.7. North America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Indication 12.8. North America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 12.8.1. Meningitis 12.8.2. Urinary Tract Infection (UTI) 12.8.3. Pneumonia 12.8.4. Hemorrhage 12.8.5. Autoimmune Diseases 12.8.6. Others 12.9. North America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by End Users 12.10. North America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 12.10.1.1. Hospital & Ambulatory Surgical Centers 12.10.1.2. Specialty Clinics 12.10.1.3. Others 12.11. North America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Country 12.12. North America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Country 12.12.1. U.S. 12.12.2. Canada 12.13. North America Systemic Inflammatory Response Syndrome Treatment Market Analysis, by Country 12.14. U.S. Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 12.14.1. Antimicrobial Therapy in SIRS 12.14.2. Steroid Therapy in SIRS 12.15. U.S. Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 12.15.1. Acute kidney injury 12.15.2. Multiple organ dysfunction syndrome 12.16. U.S. Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 12.16.1. Meningitis 12.16.2. Urinary Tract Infection (UTI) 12.16.3. Pneumonia 12.16.4. Hemorrhage 12.16.5. Autoimmune Diseases 12.16.6. Others 12.17. U.S. Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 12.17.1.1. Hospital & Ambulatory Surgical Centers 12.17.1.2. Specialty Clinics 12.17.1.3. Others 12.18. Canada Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 12.18.1. Antimicrobial Therapy in SIRS 12.18.2. Steroid Therapy in SIRS 12.19. Canada Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 12.19.1. Acute kidney injury 12.19.2. Multiple organ dysfunction syndrome 12.20. Canada Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 12.20.1. Meningitis 12.20.2. Urinary Tract Infection (UTI) 12.20.3. Pneumonia 12.20.4. Hemorrhage 12.20.5. Autoimmune Diseases 12.20.6. Others 12.21. Canada Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 12.21.1.1. Hospital & Ambulatory Surgical Centers 12.21.1.2. Specialty Clinics 12.21.1.3. Others 12.22. North America Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis 12.22.1. By Type 12.22.2. By Organ System 12.22.3. By Indication 12.22.4. By End Users 12.23. PEST Analysis 12.24. Key Trends 12.25. Key Developments 13. Europe Systemic Inflammatory Response Syndrome Treatment Market Analysis 13.1. Key Findings 13.2. Europe Systemic Inflammatory Response Syndrome Treatment Market Overview 13.3. Europe Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Type 13.4. Europe Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 13.4.1. Antimicrobial Therapy in SIRS 13.4.2. Steroid Therapy in SIRS 13.5. Europe Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Organ System 13.6. Europe Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 13.6.1. Acute kidney injury 13.6.2. Multiple organ dysfunction syndrome 13.7. Europe Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Indication 13.8. Europe Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 13.8.1. Meningitis 13.8.2. Urinary Tract Infection (UTI) 13.8.3. Pneumonia 13.8.4. Hemorrhage 13.8.5. Autoimmune Diseases 13.8.6. Others 13.9. Europe Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by End Users 13.10. Europe Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 13.10.1.1. Hospital & Ambulatory Surgical Centers 13.10.1.2. Specialty Clinics 13.10.1.3. Others 13.11. Europe Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Country 13.12. Europe Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Country 13.12.1. Germany 13.12.2. U.K. 13.12.3. France 13.12.4. Italy 13.12.5. Spain 13.12.6. Rest of Europe 13.13. Europe Systemic Inflammatory Response Syndrome Treatment Market Analysis, by Country 13.14. Germany Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 13.14.1. Antimicrobial Therapy in SIRS 13.14.2. Steroid Therapy in SIRS 13.15. Germany Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 13.15.1. Acute kidney injury 13.15.2. Multiple organ dysfunction syndrome 13.16. Germany Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 13.16.1. Meningitis 13.16.2. Urinary Tract Infection (UTI) 13.16.3. Pneumonia 13.16.4. Hemorrhage 13.16.5. Autoimmune Diseases 13.16.6. Others 13.17. Germany Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 13.17.1.1. Hospital & Ambulatory Surgical Centers 13.17.1.2. Specialty Clinics 13.17.1.3. Others 13.18. U.K. Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 13.18.1. Antimicrobial Therapy in SIRS 13.18.2. Steroid Therapy in SIRS 13.19. U.K. Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 13.19.1. Acute kidney injury 13.19.2. Multiple organ dysfunction syndrome 13.20. U.K. Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 13.20.1. Meningitis 13.20.2. Urinary Tract Infection (UTI) 13.20.3. Pneumonia 13.20.4. Hemorrhage 13.20.5. Autoimmune Diseases 13.20.6. Others 13.21. U.K. Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 13.21.1. Hospital & Ambulatory Surgical Centers 13.21.2. Specialty Clinics 13.21.3. Others 13.22. France Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 13.22.1. Antimicrobial Therapy in SIRS 13.22.2. Steroid Therapy in SIRS 13.23. France Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 13.23.1. Acute kidney injury 13.23.2. Multiple organ dysfunction syndrome 13.24. France Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 13.24.1. Meningitis 13.24.2. Urinary Tract Infection (UTI) 13.24.3. Pneumonia 13.24.4. Hemorrhage 13.24.5. Autoimmune Diseases 13.24.6. Others 13.25. France Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 13.25.1.1. Hospital & Ambulatory Surgical Centers 13.25.1.2. Specialty Clinics 13.25.1.3. Others 13.26. Italy Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 13.26.1. Antimicrobial Therapy in SIRS 13.26.2. Steroid Therapy in SIRS 13.27. Italy Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 13.27.1. Acute kidney injury 13.27.2. Multiple organ dysfunction syndrome 13.28. Italy Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 13.28.1. Meningitis 13.28.2. Urinary Tract Infection (UTI) 13.28.3. Pneumonia 13.28.4. Hemorrhage 13.28.5. Autoimmune Diseases 13.28.6. Others 13.29. Italy Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 13.29.1.1. Hospital & Ambulatory Surgical Centers 13.29.1.2. Specialty Clinics 13.29.1.3. Others 13.30. Spain Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 13.30.1. Antimicrobial Therapy in SIRS 13.30.2. Steroid Therapy in SIRS 13.31. Spain Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 13.31.1. Acute kidney injury 13.31.2. Multiple organ dysfunction syndrome 13.32. Spain Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 13.32.1. Meningitis 13.32.2. Urinary Tract Infection (UTI) 13.32.3. Pneumonia 13.32.4. Hemorrhage 13.32.5. Autoimmune Diseases 13.32.6. Others 13.33. Spain Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 13.33.1.1. Hospital & Ambulatory Surgical Centers 13.33.1.2. Specialty Clinics 13.33.1.3. Others 13.34. Rest of Europe Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 13.34.1. Antimicrobial Therapy in SIRS 13.34.2. Steroid Therapy in SIRS 13.35. Rest of Europe Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 13.35.1. Acute kidney injury 13.35.2. Multiple organ dysfunction syndrome 13.36. Rest of Europe Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 13.36.1. Meningitis 13.36.2. Urinary Tract Infection (UTI) 13.36.3. Pneumonia 13.36.4. Hemorrhage 13.36.5. Autoimmune Diseases 13.36.6. Others 13.37. Rest Of Europe Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 13.37.1.1. Hospital & Ambulatory Surgical Centers 13.37.1.2. Specialty Clinics 13.37.1.3. Others 13.38. Europe Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis 13.38.1. By Type 13.38.2. By Organ System 13.38.3. By Indication 13.38.4. By End Users 13.39. PEST Analysis 13.40. Key Trends 13.41. Key Developments 14. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Analysis 14.1. Key Findings 14.2. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Overview 14.3. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Type 14.4. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 14.4.1. Antimicrobial Therapy in SIRS 14.4.2. Steroid Therapy in SIRS 14.5. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Organ System 14.6. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 14.6.1. Acute kidney injury 14.6.2. Multiple organ dysfunction syndrome 14.7. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Indication 14.8. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 14.8.1. Meningitis 14.8.2. Urinary Tract Infection (UTI) 14.8.3. Pneumonia 14.8.4. Hemorrhage 14.8.5. Autoimmune Diseases 14.8.6. Others 14.9. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by End Users 14.10. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 14.10.1.1. Hospital & Ambulatory Surgical Centers 14.10.1.2. Specialty Clinics 14.10.1.3. Others 14.11. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Country 14.12. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Country 14.12.1. China 14.12.2. India 14.12.3. Japan 14.12.4. ASEAN 14.12.5. Rest of Asia Pacific 14.13. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Analysis, by Country 14.14. China Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 14.14.1. Antimicrobial Therapy in SIRS 14.14.2. Steroid Therapy in SIRS 14.15. China Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 14.15.1. Acute kidney injury 14.15.2. Multiple organ dysfunction syndrome 14.16. China Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 14.16.1. Meningitis 14.16.2. Urinary Tract Infection (UTI) 14.16.3. Pneumonia 14.16.4. Hemorrhage 14.16.5. Autoimmune Diseases 14.16.6. Others 14.17. China Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 14.17.1.1. Hospital & Ambulatory Surgical Centers 14.17.1.2. Specialty Clinics 14.17.1.3. Others 14.18. India Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 14.18.1. Antimicrobial Therapy in SIRS 14.18.2. Steroid Therapy in SIRS 14.19. India Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 14.19.1. Acute kidney injury 14.19.2. Multiple organ dysfunction syndrome 14.20. India Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 14.20.1. Meningitis 14.20.2. Urinary Tract Infection (UTI) 14.20.3. Pneumonia 14.20.4. Hemorrhage 14.20.5. Autoimmune Diseases 14.20.6. Others 14.21. India Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 14.21.1.1. Hospital & Ambulatory Surgical Centers 14.21.1.2. Specialty Clinics 14.21.1.3. Others 14.22. Japan Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 14.22.1. Antimicrobial Therapy in SIRS 14.22.2. Steroid Therapy in SIRS 14.23. Japan Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 14.23.1. Acute kidney injury 14.23.2. Multiple organ dysfunction syndrome 14.24. Japan Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 14.24.1. Meningitis 14.24.2. Urinary Tract Infection (UTI) 14.24.3. Pneumonia 14.24.4. Hemorrhage 14.24.5. Autoimmune Diseases 14.24.6. Others 14.25. Japan Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 14.25.1.1. Hospital & Ambulatory Surgical Centers 14.25.1.2. Specialty Clinics 14.25.1.3. Others 14.26. ASEAN Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 14.26.1. Antimicrobial Therapy in SIRS 14.26.2. Steroid Therapy in SIRS 14.27. ASEAN Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 14.27.1. Acute kidney injury 14.27.2. Multiple organ dysfunction syndrome 14.28. ASEAN Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 14.28.1. Meningitis 14.28.2. Urinary Tract Infection (UTI) 14.28.3. Pneumonia 14.28.4. Hemorrhage 14.28.5. Autoimmune Diseases 14.28.6. Others 14.29. ASEAN Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 14.29.1.1. Hospital & Ambulatory Surgical Centers 14.29.1.2. Specialty Clinics 14.29.1.3. Others 14.30. Rest of Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 14.30.1. Antimicrobial Therapy in SIRS 14.30.2. Steroid Therapy in SIRS 14.31. Rest of Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 14.31.1. Acute kidney injury 14.31.2. Multiple organ dysfunction syndrome 14.32. Rest of Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 14.32.1. Meningitis 14.32.2. Urinary Tract Infection (UTI) 14.32.3. Pneumonia 14.32.4. Hemorrhage 14.32.5. Autoimmune Diseases 14.32.6. Others 14.33. Rest of Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 14.33.1.1. Hospital & Ambulatory Surgical Centers 14.33.1.2. Specialty Clinics 14.33.1.3. Others 14.34. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis 14.34.1. By Type 14.34.2. By Organ System 14.34.3. By Indication 14.34.4. By End Users 14.35. PEST Analysis 14.36. Key Trends 14.37. Key Developments 15. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Analysis 15.1. Key Findings 15.2. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Overview 15.3. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Type 15.4. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 15.4.1. Antimicrobial Therapy in SIRS 15.4.2. Steroid Therapy in SIRS 15.5. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Organ System 15.6. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 15.6.1. Acute kidney injury 15.6.2. Multiple organ dysfunction syndrome 15.7. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Indication 15.8. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 15.8.1. Meningitis 15.8.2. Urinary Tract Infection (UTI) 15.8.3. Pneumonia 15.8.4. Hemorrhage 15.8.5. Autoimmune Diseases 15.8.6. Others 15.9. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by End Users 15.10. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 15.10.1.1. Hospital & Ambulatory Surgical Centers 15.10.1.2. Specialty Clinics 15.10.1.3. Others 15.11. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Country 15.12. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Country 15.12.1. GCC 15.12.2. South Africa 15.12.3. Rest of Middle East & Africa 15.13. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Analysis, by Country 15.14. GCC Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 15.14.1. Antimicrobial Therapy in SIRS 15.14.2. Steroid Therapy in SIRS 15.15. GCC Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 15.15.1. Acute kidney injury 15.15.2. Multiple organ dysfunction syndrome 15.16. GCC Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 15.16.1. Meningitis 15.16.2. Urinary Tract Infection (UTI) 15.16.3. Pneumonia 15.16.4. Hemorrhage 15.16.5. Autoimmune Diseases 15.16.6. Others 15.17. GCC Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 15.17.1.1. Hospital & Ambulatory Surgical Centers 15.17.1.2. Specialty Clinics 15.17.1.3. Others 15.18. South Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 15.18.1. Antimicrobial Therapy in SIRS 15.18.2. Steroid Therapy in SIRS 15.19. South Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 15.19.1. Acute kidney injury 15.19.2. Multiple organ dysfunction syndrome 15.20. South Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 15.20.1. Meningitis 15.20.2. Urinary Tract Infection (UTI) 15.20.3. Pneumonia 15.20.4. Hemorrhage 15.20.5. Autoimmune Diseases 15.20.6. Others 15.21. South Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 15.21.1.1. Hospital & Ambulatory Surgical Centers 15.21.1.2. Specialty Clinics 15.21.1.3. Others 15.22. Rest of Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 15.22.1. Antimicrobial Therapy in SIRS 15.22.2. Steroid Therapy in SIRS 15.23. Rest of Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 15.23.1. Acute kidney injury 15.23.2. Multiple organ dysfunction syndrome 15.24. Rest of Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 15.24.1. Meningitis 15.24.2. Urinary Tract Infection (UTI) 15.24.3. Pneumonia 15.24.4. Hemorrhage 15.24.5. Autoimmune Diseases 15.24.6. Others 15.25. Rest of Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 15.25.1.1. Hospital & Ambulatory Surgical Centers 15.25.1.2. Specialty Clinics 15.25.1.3. Others 15.26. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis 15.26.1. By Type 15.26.2. By Organ System 15.26.3. By Indication 15.26.4. By End Users 15.27. PEST Analysis 15.28. Key Trends 15.29. Key Developments 16. South America Systemic Inflammatory Response Syndrome Treatment Market Analysis 16.1. Key Findings 16.2. South America Systemic Inflammatory Response Syndrome Treatment Market Overview 16.3. South America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Type 16.4. South America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 16.4.1. Antimicrobial Therapy in SIRS 16.4.2. Steroid Therapy in SIRS 16.5. South America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Organ System 16.6. South America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 16.6.1. Acute kidney injury 16.6.2. Multiple organ dysfunction syndrome 16.7. South America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Indication 16.8. South America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 16.8.1. Meningitis 16.8.2. Urinary Tract Infection (UTI) 16.8.3. Pneumonia 16.8.4. Hemorrhage 16.8.5. Autoimmune Diseases 16.8.6. Others 16.9. South America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by End Users 16.10. South America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 16.10.1.1. Hospital & Ambulatory Surgical Centers 16.10.1.2. Specialty Clinics 16.10.1.3. Others 16.11. South America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Country 16.12. South America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Country 16.12.1. Brazil 16.12.2. Mexico 16.12.3. Rest of South America 16.13. South America Systemic Inflammatory Response Syndrome Treatment Market Analysis, by Country 16.14. Brazil Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 16.14.1. Antimicrobial Therapy in SIRS 16.14.2. Steroid Therapy in SIRS 16.15. Brazil Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 16.15.1. Acute kidney injury 16.15.2. Multiple organ dysfunction syndrome 16.16. Brazil Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 16.16.1. Meningitis 16.16.2. Urinary Tract Infection (UTI) 16.16.3. Pneumonia 16.16.4. Hemorrhage 16.16.5. Autoimmune Diseases 16.16.6. Others 16.17. Brazil Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 16.17.1.1. Hospital & Ambulatory Surgical Centers 16.17.1.2. Specialty Clinics 16.17.1.3. Others 16.18. Mexico Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 16.18.1. Antimicrobial Therapy in SIRS 16.18.2. Steroid Therapy in SIRS 16.19. Mexico Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 16.19.1. Acute kidney injury 16.19.2. Multiple organ dysfunction syndrome 16.20. Mexico Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 16.20.1. Meningitis 16.20.2. Urinary Tract Infection (UTI) 16.20.3. Pneumonia 16.20.4. Hemorrhage 16.20.5. Autoimmune Diseases 16.20.6. Others 16.21. Mexico Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 16.21.1.1. Hospital & Ambulatory Surgical Centers 16.21.1.2. Specialty Clinics 16.21.1.3. Others 16.22. Rest of South America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Type 16.22.1. Antimicrobial Therapy in SIRS 16.22.2. Steroid Therapy in SIRS 16.23. Rest of South America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Organ System 16.23.1. Acute kidney injury 16.23.2. Multiple organ dysfunction syndrome 16.24. Rest of South America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by Indication 16.24.1. Meningitis 16.24.2. Urinary Tract Infection (UTI) 16.24.3. Pneumonia 16.24.4. Hemorrhage 16.24.5. Autoimmune Diseases 16.24.6. Others 16.25. Rest of South America Systemic Inflammatory Response Syndrome Treatment Market Forecast, by End Users 16.25.1.1. Hospital & Ambulatory Surgical Centers 16.25.1.2. Specialty Clinics 16.25.1.3. Others 16.26. South America Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis 16.26.1. By Type 16.26.2. By Organ System 16.26.3. By Indication 16.26.4. By End Users 16.27. PEST Analysis 16.28. Key Trends 16.29. Key Developments 17. Company Profiles 17.1. Market Share Analysis, by Company 17.2. Competition Matrix 17.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 17.2.2. New Product Launches and Product Enhancements 17.2.3. Market Consolidation 17.2.3.1. M&A by Regions, Investment and Applications 17.2.3.2. M&A Key Players, Forward Integration and Backward Integration 17.3. Company Profiles: Key Players 17.3.1. UnitedHealth Group 17.3.1.1. Company Overview 17.3.1.2. Financial Overview 17.3.1.3. Product Portfolio 17.3.1.4. Business Strategy 17.3.1.5. Recent Developments 17.3.1.6. Company Footprint 17.3.2. CytoSorbents Corporation 17.3.3. RegeneRx Biopharmaceuticals, Inc. 17.3.4. Endacea Inc. 17.3.5. Adrenomed AG 17.3.6. GlaxoSmithKline plc 17.3.7. Asahi Kasei Corporation 17.3.8. Cardinal Health 17.3.9. Smith & 17.3.10. Nephew plc 17.3.11. ConvaTec, Inc. 17.3.12. AstraZeneca 17.3.13. Orion Corporation 17.3.14. CHIESI Farmaceutici S.p.A. 17.3.15. Mylan N.V 18. Primary Key Insights